1. Home
  2. SPRO vs OPXS Comparison

SPRO vs OPXS Comparison

Compare SPRO & OPXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

SELL

Current Price

$1.10

Market Cap

67.0M

Sector

Health Care

ML Signal

SELL

Logo Optex Systems Holdings Inc.

OPXS

Optex Systems Holdings Inc.

SELL

Current Price

$9.82

Market Cap

70.9M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
SPRO
OPXS
Founded
2013
1987
Country
United States
United States
Employees
N/A
72
Industry
Biotechnology: Pharmaceutical Preparations
Electronic Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
70.9M
IPO Year
2017
2009

Fundamental Metrics

Financial Performance
Metric
SPRO
OPXS
Price
$1.10
$9.82
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $5.00
N/A
AVG Volume (30 Days)
★ 839.8K
19.7K
Earning Date
11-12-2026
08-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 111.81
34.55
EPS
N/A
★ 0.41
Revenue
★ $66,802,000.00
$24,530,000.00
Revenue This Year
N/A
$3.54
Revenue Next Year
N/A
$10.05
P/E Ratio
★ N/A
$24.29
Revenue Growth
★ 39.24
17.63
52 Week Low
$1.08
$9.04
52 Week High
$3.08
$17.76

Technical Indicators

Market Signals
Indicator
SPRO
OPXS
Relative Strength Index (RSI) 41.51 38.72
Support Level $1.10 $9.04
Resistance Level $1.28 $10.85
Average True Range (ATR) 0.06 0.31
MACD -0.01 -0.02
Stochastic Oscillator 2.50 17.39

Price Performance

Historical Comparison
SPRO
OPXS

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About OPXS Optex Systems Holdings Inc.

Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.

Share on Social Networks: